



M. Micaëlo¹⁻⁴, H. Jacquier¹⁻⁴, E. Cambau¹⁻⁴, G. La Ruche⁵, P. Sednaoui⁶, A. Goubard⁶, B. Berçot¹⁻⁴

¹ Department of Bacteriology-Virology, Assistance Publique/Hôpitaux de Paris, Lariboisière-St Louis-Fernand Widal Group, Paris, France;

² Associated Laboratory of the National Center for *Neisseria gonorrhoeae*, Paris, France;

³ IAME, UMR 1137, INSERM, F-75018 Paris, France; ⁴ University Paris Diderot, Sorbonne Paris Cité, F-75018 Paris, France;

⁶ HIV/AIDS-STI-HCV unit, Department of Infectious Diseases, French Institute for Public Health Surveillance, Saint-Maurice, France;

⁶ Institute Alfred Fournier, National Center for *Neisseria gonorrhoeae*, Paris, France;

Introduction

Acquired resistance to β -lactams in *Neisseria gonorrhoeae* (NG) is mainly related to:

- ✓ target modification (PLP2 mosaicism)
- ✓ efflux or decrease in permeability
- ✓ β -lactamase production, especially TEM-1 β -lactamase.

In 2012, 9% of NG strains isolated in France was β -lactamase producers (1). Although class A TEM-1 β -lactamase was classically described for NG, a recent emergence of TEM-135 has been described in Asia (2).

Objective

The **objective** of this work was to explore the β -lactamase enzymes and their genetic support for NG-producing β -lactamase clinical isolates from France.

Methods

From December 2010 to October 2012, 177 penicillinase-producing *N. gonorrhoeae* (PPNG) strains were isolated in the French Reference National Center.

Penicillinase production was detected by performing the nitrocefin reference test (cefinaise, Biomerieux). MICs were determined using the E-test method. DNA was extracted by using Instagene Matrix (Biorad®) and the entire *bla*_{TEM} gene was amplified and sequenced using OT3/OT4 and two additional internal primers.

The complete sequence of 22 plasmids carrying *bla*_{TEM-135} and *bla*_{TEM-1} were determined. Plasmid DNA extraction was performed using the QIAprep Spin Miniprep kit (Qiagen®). Plasmid sequences were obtained by PCR mapping, sequencing and alignment on Bioedit software.

Molecular epidemiology typing was performed by the reference Multi-Antigen Sequence Typing (NG-MAST) method (3). Each strain ST was determined using the NG-MAST database (4).

Results and discussion

- For the 177 penicillinase-producing *N. gonorrhoeae* clinical isolates, MICs to ceftriaxone varied from 0.002 to 0.032 mg/L and MICs to cefixime varied from <0.016 to 0.064 mg/L.

- All the 177 PPNG isolates harboured the *bla*_{TEM} genes encoding several variants of the TEM enzymes:

- ✓ 152 (86%) TEM-1
- ✓ 14 (8%) TEM-135 (mutation M182T)
- ✓ 11 (6%) other TEM variants not yet described (cf. Table)

- Complete sequencing of 22 plasmids of interest (cf. Table) found that:
 - the *bla*_{TEM-135} genes were carried on two different plasmids quite identical to the pJD4 or pJD7 plasmid previously described (5).
 - the other *bla*_{TEM} alleles were carried by the pJD5 plasmid.

- According to NG-MAST Sequence Type (ST), 10 different ST were observed for NG expressing the TEM-135 enzyme suggesting that the diffusion of this variant is not linked to a clonal diffusion. Additionally, these ST were different than those found in Asia (2)

Conclusions

This work illustrates the recent evolution of plasmid-encoded *bla*_{TEM} found in *N. gonorrhoeae* from France and highlights their localisation in several genetic backgrounds.

As the mutation M182T has been described as a stabilizing mutation (6), this study suggests a possible emergence of extended spectrum β -lactamase-producing NG in the future.

Table: Characteristics of 22 NG isolates expressing the TEM-135 and TEM-1 variants Tet: Tetracycline, Cip: ciprofloxacin, ND: not determined, *: 99% homology)

NG isolates	Mutations (TEM variant)	Plasmids	MIC ceftriaxone (mg/L)	MIC cefixime (mg/L)	Coreistance	ST types (NG-MAST)
S3			0.032	0.064	Tet ^R Cip ^K	STND-A
S19	M182T (TEM-135)	pJD7 Toronto / Rio (5.2 Kb)	0.004	0.016	Tet ^K Cip ^K	ST5060
S51			0.002	0.016	Tet ^K Cip ^K	ST5624
S93			0.003	0.016	Tet ^R Cip ^R	ST758
S188			0.002	0.016	Tet ND Cip ^R	ST1737 *
S111, S113	M182T (TEM-135)	pJD4 Asian (7.4 Kb)	0.003	0.016	Tet ^R Cip ^R	ST4995
S36			0.023	0.047	Tet ^K Cip ^R	ST2485
S63			0.016	0.016	Tet ^K Cip ^R	ST3873
S104, S182			0.002	0.016	Tet ND Cip ^R	STND-B
S119, S20			0.002	0.016	Tet ^R Cip ^R	STND-C
S18, S49	P14S (TEM-1)	pJD5 African (5.5 Kb)	0.003	0.016	Tet ^R	ST5268
S54	Q269K (TEM-1)		0.006	0.016	Tet ^K Cip ^K	ST3109
S172	G228S (TEM-1)		0.016	0.032	Tet ^{NU} Cip ^K	STND-D
S177	P14L (TEM-1)		0.003	0.016	Tet ^{NU}	ST4915 *
S2			0.032	0.064	Tet ^K Cip ^K	ST5526 *
S4	WT (TEM-1)		0.023	0.023	Tet ^K Cip ^R	ST3307
S11		0.003	0.016	Tet ^R Cip ^R	STND-E	
S1		0.023	0.023	Tet ^R Cip ^R	ST1288	

References

- 1) Centre National de Référence des Gonocoques. Rapport d'activité 2012.
- 2) Ohnishi M. *et al.*, Antimicrob. Agents Chemother. 2010;54(7):3021-3023.
- 3) Unemo M. *et al.*, Clinical Microbiology Reviews. 2011;24(3):447-458.
- 4) <http://www.ng-mast.net/>
- 5) Pagotto F. *et al.*, Plasmid, 2000;43(1):24-34
- 6) Jacquier *et al.*, Proc Natl Acad Sci, 2013;110(32):13067-72.

We would like to thank to all biologists participating to the RENAGO network